Yet, while the growth story sounds appealing, investors should also be aware of how regulatory and legal pressures around GLP-1s could still
Comer To view or add a comment, sign in Obesity Drugs: Market Impact in 2025+ The obesity drug market is reshaping pharma at record speed
Acamprosate, whose mechanism of action involves modulating the glutamate system, is also approved to treat AUD
Tirzepatide, administered as a weekly subcutaneous injection, and additional dual GLP-1/GIP receptor agonists that could eventually be developed in the future seem to be a promising furthest advance for the management of several cardiometabolic settings
Advances in oral peptide therapeutics
These dietary supplements were conceived and developed to address key nutrient deficiencies that may occur when a person's appetite is significantly reduced